Immunocore Holdings (IMCR) Operating Leases (2019 - 2026)

Immunocore Holdings (IMCR) has reported Operating Leases for 8 consecutive years, with $42.0 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Leases fell 1.04% year-over-year to $42.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.0 million (down 1.04% YoY) and the FY2025 annual result came in at $41.6 million, up 3.47% from the prior year.
• Operating Leases grew to $42.0 million in Q1 2026 per IMCR's latest filing, from $41.6 million in the prior quarter.
• Over the last five years, Operating Leases for IMCR reached as high as $44.4 million in Q2 2025 and fell as low as $31.8 million in Q3 2022.
• A 5-year average of $38.6 million and a median of $40.2 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases slipped 3.06% — and 2025, when it advanced 27.48%.
• Year by year, Operating Leases stood at $33.1 million in 2022, then increased by 7.48% to $35.6 million in 2023, then gained by 12.78% to $40.2 million in 2024, then advanced by 3.47% to $41.6 million in 2025, then gained by 1.12% to $42.0 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $42.0 million, $41.6 million, and $43.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.